Inhibitory actions of sulindac on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients.
Arylamine N-acetyltransferase (NAT) activity in Helicobacter pylori was inhibited by sulindac, a drug proposed for cancer prevention. The NAT activity was determined using an acetyl CoA recycling assay and HPLC. Inhibition of growth studies from H. pylori demonstrated that sulindac elicited a dose-dependent bactericidal effect in H. pylori cultures, that is, the greater the concentration of sulindac, the greater the inhibition of growth of H. pylori. The IC(50) value was 4mm for inhibition growth of H. pylori. Cytosols or suspensions of H. pylori with and without selected concentrations of sulindac co-treatment showed different percentages of 2-aminofluorene and p-aminobenzoic acid acetylation. The data indicated that there was decreased NAT activity associated with increased sulindac in H. pylori cytosols and intact cells (IC(50) values were 4mm). For the cytosol and intact bacteria examinations, the apparent values of K(m) and V(max) were decreased after co-treatment with 4mm sulindac. This report is the first demonstration of sulindac inhibition of arylamine NAT activity and sulindac inhibition of growth in the bacterium H. pylori.